EgtD Histidine Transmethylase Mutants for Rate-Limiting EGT Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing ergothioneine (EGT) suffer from low yield and long growth cycles in EgtD enzyme activity, which is a rate-limiting step in the biosynthetic pathway, making it unsuitable for industrial production.
Innovation Solution
Development of histidine transmethylase EgtD mutants with specific amino acid substitutions (S70V, S70N, S70K, S70W) to enhance enzyme activity, combined with other enzymes in the EGT synthetic pathway, using genetic recombination and expression in microorganism systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type EgtD is used for EGT production, then the biosynthetic pathway is complete, but the enzymatic activity is too low (0.58 s⁻¹) to meet industrial production requirements
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues (S70V, S70N, S70K, S70W) in the EgtD enzyme to alter its catalytic properties. These point mutations change the local chemical environment and substrate binding characteristics, resulting in significantly improved enzymatic activity while maintaining the enzyme's structural stability and functional reliability.
Solution Approach 2:
The patent implements local quality by focusing mutations on specific critical residues (position 70) within the enzyme's active site or substrate binding region. This localized modification approach improves catalytic efficiency without disrupting the overall enzyme structure and function, allowing the majority of the enzyme to maintain its original stable properties while the local mutated region provides enhanced activity.
2Productivity
If chemical synthesis or extraction from natural products is used, then EGT can be obtained, but the output is low, impurities are high, and costs are high
Solution Approach 1:
The patent employs self-service by using genetically engineered microorganisms that autonomously produce EGT through their metabolic pathways. The engineered EgtD mutant enzyme operates within the microbial system to convert histidine to ergothioneine, eliminating the need for external chemical synthesis or complex extraction processes, thereby reducing costs and improving purity through the organism's natural metabolic regulation.
Solution Approach 2:
The patent replaces mechanical/chemical extraction and synthesis methods with a biological system. Instead of using chemical reagents and complex purification equipment, the invention uses engineered microorganisms with mutated EgtD enzyme to biosynthesize EGT, substituting chemical mechanics with biological catalysis that occurs under mild conditions with inherent selectivity.
3Reliability
If existing EgtD variants are used, then some catalytic activity is achieved, but the activity is only 2.3% of the most active EgtE enzyme, making it rate-limiting
Solution Approach 1:
The patent applies parameter changes by systematically mutating amino acid residues in EgtD to optimize its catalytic parameters. The S70V, S70N, S70K, and S70W mutations specifically alter the enzyme's turnover number and substrate affinity, bringing its activity level closer to that of EgtE and eliminating it as the rate-limiting step in the pathway.
Solution Approach 2:
The patent achieves universality by creating EgtD variants that can function effectively alongside EgtE and other pathway enzymes. The mutated EgtD maintains compatibility with the overall metabolic pathway while achieving catalytic activity levels that allow it to function cooperatively with other enzymes, transforming it from a bottleneck to an integrated component of the EGT biosynthetic system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EgtD mutants significantly improve EGT production by 22-24 times, providing a novel synthetic pathway and engineering bacterium for efficient EGT production.
Implementation Method 1
The first step of the biosynthetic pathway of EGT is that histidine is catalyzed by a SAM (S-adenosylmethionine)-dependent histidine trimethylase (EgtD) and transformed into Hercynine (HER for short)
Data Source
AI summary
The present invention falls within the technical field of genetic engineering, and specifically provides a histidine transmethylase mutant and use thereof. The mutant protein has significantly improved catalytic activity over a parent protein and thus, promotes the production of ergothioneine (L-EGT) catalyzed by the histidine transmethylase, which provides a novel synthetic pathway and engineering bacterium for the production of L-EGT.